Magnesium potassium citrate is a mixture of potassium, magnesium and citrate in the proportions 4 to 1 to 2, respectively. Magnesium potassium citrate has been proven to be an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. Liquid magnesium potassium citrate has been studied in clinical trial for controlling hypertension. Provision of alkali as magnesium potassium citrate is an effective countermeasure for the increased risk of renal stone disease associated with immobilization. Magnesium potassium citrate is a nutritional supplement that fights kidney stones.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Magnesium Potassium Citrate, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.